Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial

Aspirin-free antiplatelet regimens after PCI: when is it best to stop aspirin and who could ultimately benefit?

(2020) Mariusz Tomaniak et al.   EuroIntervention

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk

(2019) Philip Urban et al.   EUROPEAN HEART JOURNAL

Validation of National Cardiovascular Data Registry risk models for mortality, bleeding and acute kidney injury in interventional cardiology at a German Heart Center

(2019) Georg Wolff et al.   Clinical Research in Cardiology

Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial

(2019) Patrick W Serruys et al.   EUROPEAN HEART JOURNAL

Ticagrelor with or without Aspirin in High-Risk Patients after PCI

(2019) Roxana Mehran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

(2019) Stefanie Schüpke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University

(2018) Nikolaus Marx et al.   Clinical Research in Cardiology

Standardized End Point Definitions for Coronary Intervention Trials

(2018) Hector M Garcia-Garcia et al.   EUROPEAN HEART JOURNAL

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention

(2018) Davide Capodanno et al.   Nature Reviews Cardiology

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

(2018) Pascal Vranckx et al.   LANCET

Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease

(2018) Marc Laine et al.   THROMBOSIS AND HAEMOSTASIS

P2Y 12 -ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes

(2018) Laurent Bonello et al.   CIRCULATION

Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest

(2018) Kathrin Weidner et al.   Clinical Research in Cardiology

Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study

(2016) Usman Baber et al.   AMERICAN HEART JOURNAL

Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors

(2016) Seung-Yul Lee et al.   Clinical Research in Cardiology

Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial

(2016) Pascal Vranckx et al.   EuroIntervention

Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70years and older—rationale and design of the POPular AGE study

(2015) Khalid Qaderdan et al.   AMERICAN HEART JOURNAL

Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease: Results From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Registry

(2015) U. Baber et al.   Circulation-Cardiovascular Interventions

Defining the Link Between Chronic Kidney Disease, High Platelet Reactivity, and Clinical Outcomes in Clopidogrel-Treated Patients Undergoing Percutaneous Coronary Intervention

(2015) F. Franchi et al.   Circulation-Cardiovascular Interventions

Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes

(2015) Marco Valgimigli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

(2015) Marc P. Bonaca et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline

(2013) Paul E. Stevens   ANNALS OF INTERNAL MEDICINE

Haemostasis in chronic kidney disease

(2013) Jens Lutz et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Antithrombotic Therapy in Patients With Chronic Kidney Disease

(2012) Davide Capodanno et al.   CIRCULATION

Standardized Bleeding Definitions for Cardiovascular Clinical Trials

(2011) Roxana Mehran et al.   CIRCULATION

Ticagrelor in the Renal Dysfunction Subgroup: Subjugated or Substantiated?

(2010) Gilles Montalescot et al.   CIRCULATION

Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function

(2010) Stefan James et al.   CIRCULATION

Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy

(2010) Dominick J. Angiolillo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Renal function, atherothrombosis extent, and outcomes in high-risk patients

(2009) Raphaelle L. Dumaine et al.   AMERICAN HEART JOURNAL

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial

(2008) Stephan Windecker et al.   LANCET